Innovation
The difference between an idea and innovation is follow-through
Creating the next great innovations in life sciences takes the best minds, the smartest tools and technologies, the most rigorous processes and the strongest wills. With the barriers so high and the need for innovation so urgent, the difference between success and failure can be the right partner to spark inspiration and keep moving projects forward. Maravai strives to be that ally.
For over 35 years, Maravai’s portfolio companies have served as a catalyst for innovative,
lifesaving technology for humanity. Pioneering nucleotide research since its inception, we are now leading the way in the rapidly expanding mRNA market.
BY THE NUMBERS
Delivering innovation by every measure
How is Maravai realizing the future of medicine? Here are just a few of the countless breakthroughs and extraordinary accomplishments stemming from our brands’ innovations.
3500+ products
Maravai brands offer more than 3,500+ products in our portfolio, including TriLink’s flagship product CleanCap®, our novel mRNA capping solution.
State-of-the-art LC-MS capabilities
Advanced analytical methods for host cell protein identification and quantification help ensure biopharmaceutical purity and quality throughout process development and final drug substance testing.
Up to 10x protein expression
TriLink’s novel, proprietary ModTail™ poly(A) tail modification increases and extends the duration of protein expression, helping mRNA reach its full potential in research and therapeutic applications.
Reduce dsRNA formation by 80%
CleanScribe™ RNA Polymerase reduces dsRNA formation by up to 80% versus standard wild-type T7 RNA polymerases across internal and customer studies.
Simplifying IVT, elevating results
TriLink’s kits deliver industry-leading mRNA yield with minimal dsRNA byproduct – driving up to 4.8x higher protein expression compared to leading IVT kits. Combine CleanCap® IVT and ModTail™ kits for cumulative gains in mRNA performance.
29 out of 29
29 out of 29 approved CAR-T cell and gene therapies rely on Maravai’s Cygnus testing solutions to assure their purity and safety.
5+ billion vaccine doses shipped globally
Our proprietary CleanCap® technology was used in the world’s first FDA-approved mRNA vaccine, jointly developed by Pfizer and BioNTech. Over 5 billion of these vaccines have been shipped to 181 countries in every region of the world.
1-2 days, not months
The revolutionary Cygnus MockV® RVLP Kit utilizes a non-infectious RVLP spiking agent, enabling companies to perform these viral clearance tests at their own laboratory bench, for a fraction of the cost and in a fraction of the time of a live study.